<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CEFDINIR</span><br/>(cef'di-nir)<br/><span class="topboxtradename">Omnicef<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">third-generation cephalosporin</span><br/><b>Prototype: </b>Cefotaxime Sodium<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>300 mg capsules; 125 mg/5 mL suspension</p>
<h1><a name="action">Actions</a></h1>
<p>Broad-spectrum semi-synthetic third-generation cephalosporin antibiotic. Generally active against a wide variety of gram-positive
         and gram-negative bacteria.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against most <i>Enterobacteriaceae</i> and <i>Pseudomonas,</i> and most strains of <i>Staphylococci</i> and <i>Streptococci</i> including methicillin-resistant strains (MRSA). Effectively treats pneumonia, acute and chronic bronchitis, otitis media,
         sinusitis, vaginitis, and skin infections reducing or eliminating signs and symptoms of infection.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Community-acquired pneumonia, acute exacerbations of chronic bronchitis, acute maxillary sinusitis, pharyngitis, tonsillitis,
         uncomplicated skin infections, bacterial otitis media.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to cefdinir and other cephalosporins; pregnancy (category B).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypersensitivity to penicillins, penicillin derivatives; renal impairment; ulcerative colitis or antibiotic-induced colitis;
         bleeding disorders; lactation; GI disorders; liver or kidney disease. Safety and efficacy in neonates and infants 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Community-Acquired Pneumonia, Skin Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 300 mg q12h times 10 d<br/><span class="rdage">Child <i>6 mo12 y</i>
                  				:</span> <span class="rdroute">PO</span> 7 mg/kg q12h times 10 d<br/><br/><span class="indicationtitle">Chronic Bronchitis, Maxillary Sinusitis, Pharyngitis, Tonsillitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 600 mg q24h or 300 mg q12h times 10 d<br/><span class="rdage">Child <i>6 mo12 y</i>
                  				:</span> <span class="rdroute">PO</span> 14 mg/kg q24h or 7 mg/kg q12h times 10 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not give within 2 h of aluminum- or magnesium-containing antacids or iron supplements.</li>
<li>Reconstitute oral suspension to 125 mg/mL by adding water (38-mL to 60-mL bottle or 63-mL to 100-mL bottle). Shake well before
            each use.
         </li>
<li>Consult physician for dosage adjustment if creatinine clearance 
         </li><li>Store in tightly closed container. Discard after 10 days.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> GI:</span>
<span class="speceff-common">Diarrhea,</span> nausea, abdominal pain. <span class="typehead">Metabolic:</span> Increased GGT, increased urine protein, hematuria. <span class="typehead">CNS:</span> Headache. <span class="typehead">Skin:</span> Rash, cutaneous moniliasis. <span class="typehead">Urogenital:</span> Vaginal moniliasis, vaginitis. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>False positive for <span class="alt">ketones</span> or <span class="alt">glucose</span> in urine using <span class="alt">nitroprusside</span> or <span class="alt">Clinitest.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<span class="classification">Antacids</span> should be taken at least 2 h before or after cefdinir; <b>probenecid</b> prolongs cefdinir elimination; <b>iron</b> decreases absorption. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 1625% bioavailability. <span class="typehead">Peak:</span> 24 h. <span class="typehead">Distribution:</span> 6070% protein bound; penetrates sinus tissue, blister fluid, lung tissue, middle ear fluid. <span class="typehead">Metabolism:</span> Not metabolized. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 1.6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Determine previous hypersensitivity to cephalosporins, penicillins, and other drug allergies before therapy is initiated.</li>
<li>Carefully monitor for and immediately report S&amp;S of: hypersensitivity, superinfection, or pseudomembranous colitis (see Appendix
            F).
         </li>
<li>Discontinue drug and notify physician if seizures associated with drug therapy occur.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Allow a minimum of 2 h between cefdinir and antacids containing aluminum or magnesium, or drugs containing iron.</li>
<li>Immediately contact physician if a rash, diarrhea, or new infection (e.g., yeast infection) develops.</li>
<li>Drug may cause false positive for urine ketones or glucose. Consult package insert.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>